LifeMD (NASDAQ:LFMD) Issues Quarterly Earnings Results

LifeMD (NASDAQ:LFMD) issued its quarterly earnings results on Monday. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.04), Zacks reports. The firm had revenue of $60.17 million during the quarter, compared to the consensus estimate of $62.07 million. During the same period in the previous year, the business posted $0.09 EPS. LifeMD updated its FY 2025 guidance to EPS and its Q4 2025 guidance to EPS.

LifeMD Stock Down 13.5%

Shares of NASDAQ LFMD opened at $4.09 on Wednesday. LifeMD has a 1 year low of $3.43 and a 1 year high of $15.84. The firm’s 50-day moving average is $6.01 and its 200-day moving average is $8.68. The company has a current ratio of 0.77, a quick ratio of 0.72 and a debt-to-equity ratio of 9.21. The firm has a market capitalization of $193.94 million, a PE ratio of -24.06 and a beta of 1.57.

Insiders Place Their Bets

In other LifeMD news, insider Nicholas P. Alvarez sold 75,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $5.92, for a total value of $444,000.00. Following the transaction, the insider directly owned 605,000 shares of the company’s stock, valued at approximately $3,581,600. This trade represents a 11.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 18.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On LifeMD

A number of institutional investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC grew its position in shares of LifeMD by 110.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock worth $64,000 after buying an additional 2,452 shares during the period. Quarry LP bought a new position in shares of LifeMD during the third quarter worth $52,000. Legal & General Group Plc raised its stake in LifeMD by 187.4% during the 2nd quarter. Legal & General Group Plc now owns 10,144 shares of the company’s stock worth $138,000 after buying an additional 6,614 shares during the period. Hudson Bay Capital Management LP bought a new position in LifeMD during the second quarter worth about $153,000. Finally, New York State Common Retirement Fund grew its stake in LifeMD by 2,180.0% in the second quarter. New York State Common Retirement Fund now owns 11,400 shares of the company’s stock valued at $155,000 after acquiring an additional 10,900 shares during the period. 35.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on LFMD. Weiss Ratings reissued a “sell (d-)” rating on shares of LifeMD in a report on Wednesday, October 8th. HC Wainwright dropped their price objective on LifeMD from $14.00 to $13.00 and set a “buy” rating for the company in a research note on Thursday, August 7th. Wall Street Zen downgraded shares of LifeMD from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. KeyCorp dropped their target price on shares of LifeMD from $14.00 to $12.00 and set an “overweight” rating for the company in a research report on Wednesday, August 6th. Finally, Zacks Research raised shares of LifeMD from a “strong sell” rating to a “hold” rating in a report on Friday, September 5th. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, LifeMD has an average rating of “Moderate Buy” and an average target price of $10.71.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.